Affymetrix Posts 12 Percent Revenue Drop, Amends Deal for eBioscience | GenomeWeb

NEW YORK (GenomeWeb News) – Affymetrix reported after the close of the market on Thursday that revenues in the first quarter dropped 12 percent year over year.

The Santa Clara, Calif.-based microarray company also announced separately that it has signed an amended deal to acquire eBioscience for $315 million in cash.

Affy's revenues for the three months ended March 31 dropped to $65.2 million, down from $73.7 million a year ago, but still above Wall Street estimates of $64.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.